Hexima Limited

HXL

AU0000111932

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:10 2024-04-22 am EDT			5-day change	1st Jan Change
0.013 ^AUD	0.00%		0.00%	-27.78%

Mar. 22	Hexima Secures R&D Tax Rebate for Fiscal Year 2023	MT
Mar. 19	Hexima Changes Address	MT

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

May 11, 2023 at 04:31 am EDT

Hexima Limited announced the resignation of Mr. Steven Skala as an alternate director of the Company, effective 11 May 2023.

Latest news about Hexima Limited

Hexima Secures R&D Tax Rebate for Fiscal Year 2023	Mar. 21	MT
Hexima Changes Address	Mar. 19	MT
Hexima Limited Announces Change of Address	Mar. 19	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28	CI
Hexima Limited Announces the Resignation of Dr. Nicole Van Der Weerden as Director	Nov. 29	CI
Hexima Limited Appoints Phillip Hains as A Non-Executive Director	23-09-18	CI
Hexima Limited Appoints Geoffrey Kempler as Managing Director	23-09-05	CI
Hexima Limited Announces Executive Changes	23-09-05	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director	23-05-11	CI
Hexima Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-27	CI
Hexima Limited Declares Voting Results	23-01-30	CI
Arovella Therapeutics Appoints COO	23-01-03	MT
Hexima Acting CEO to Step Down	22-12-22	MT
Nicole Van Der Weerden to Step Down as CEO of Hexima Limited	22-12-22	CI
Hexima Receives AU$6 Million Tax Incentive Refund from Australian Taxation Office	22-12-14	MT
Hexima Limited Receives Requisition Notice from Merchant Biotech Fund	22-12-13	CI
Hexima Limited Announces Board Changes	22-12-04	CI
10,150,000 Options of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	22-11-30	CI
6,925,878 Ordinary Shares of Hexima Limited are subject to a Lock-Up Agreement Ending on 1-DEC-2022.	22-11-30	CI
Hexima Limited Announces Change of Address	22-09-12	CI
Hexima Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-30	CI
Hexima Managing Director, CEO Steps Down	22-08-02	MT
Hexima Limited Announces Management Changes	22-08-01	CI
Hexima Limited Announces Phase II Results of Pezadeftide	22-07-10	CI

Hexima Limited is an Australia-based clinical-stage, anti-infectives focused biotechnology company. The Company is engaged in the research and development of plant defensin peptides for applications in human therapeutics. Its lead drug candidate is the plant defensin, pezadeftide, developed for the treatment of fungal nail infections. The Company is conducting phase II clinical trial testing pezadeftide as a treatment for onychomycosis. Its Antifungal Plant Defensin Technology platform is engaged in identifying several plant peptides with potent antifungal activity against a broad range of human fungal pathogens. It is also investigating the application of its plant defensin technology to other human fungal diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
HEXIMA LIMITED	-27.78%	1.41M
IQVIA HOLDINGS INC.	+0.69%	43.84B
MODERNA, INC.	+4.87%	41.68B
LONZA GROUP AG	+45.43%	41.25B
CELLTRION, INC.	-11.96%	27.04B
ICON PUBLIC LIMITED COMPANY	+6.14%	25.53B
ALNYLAM PHARMACEUTICALS, INC.	-25.34%	18.18B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.94%	12.29B
MEDPACE HOLDINGS, INC.	+25.48%	12.29B
UNITED THERAPEUTICS CORPORATION	+7.20%	11.15B

Other Biotechnology & Medical Research

Hexima Limited

Equities

HXL

AU0000111932

Biotechnology & Medical Research

Hexima Limited Announces Resignation of Mr. Steven Skala as an Alternate Director

Latest news about Hexima Limited

Chart Hexima Limited

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Other Biotechnology & Medical Research